OCUL
Ocular Therapeutix Inc
NASDAQ · Pharmaceuticals
$9.16
+0.25 (+2.81%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 85.77M | 75.54M | 415.51M | 384.00M | 364.41M |
| Net Income | -260,493,138 | -206,467,480 | 55.42M | 56.73M | 50.92M |
| EPS | — | — | — | — | — |
| Profit Margin | -303.7% | -288.5% | 13.3% | 14.8% | 14.0% |
| Rev Growth | +13.6% | +13.6% | +9.7% | -3.5% | -8.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 174.12M | 174.12M | 519.56M | 542.51M | 619.03M |
| Total Equity | 801.64M | 801.64M | 1.41B | 1.53B | 1.48B |
| D/E Ratio | 0.22 | 0.22 | 0.37 | 0.35 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -263,774,069 | -220,682,840 | 92.87M | 95.97M | 85.28M |
| Free Cash Flow | — | — | 50.89M | 61.23M | 57.18M |